Effects of ceruletide on perioral movements and the dopamine receptor-adenylate cyclase system in rats chronically treated with fluphenazine

Psychopharmacology

Volumn 125, Issue 3, 1996, Pages 185-194

  Ashizawa, Takeshi ^a   Saito, Toshikazu ^a   Takahata, Naohiko ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

adenylate cyclase; ceruletide; chronic fluphenazine; D1 receptor; tardive dyskinesia

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENYLATE CYCLASE; BUTACLAMOL; CERULETIDE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUPHENAZINE ENANTHATE; GUANYLYLIMIDODIPHOSPHATE; KETANSERIN; RADIOLIGAND; SPIPERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN MEMBRANE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; ELECTROMYOGRAM; ENZYME ACTIVITY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MASTICATION; MOUTH; NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; RAT; TARDIVE DYSKINESIA; TONGUE; TREMOR;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ADENYLATE CYCLASE; ANIMALS; BEHAVIOR, ANIMAL; CAERULEIN; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; ELECTROMYOGRAPHY; FLUPHENAZINE; MALE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SPIPERONE;

EID: 0030012916     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02247327     Document Type: Article

References (57)

1. 1 receptor antagonist ligand, in rat striatum. Life Sci 35: 1885-1893
2. Clow A, Jenner P, Marsden CD (1979) Changes in dopamine-mediated behavior during one year's neuroleptic administration. Eur J Pharmacol 57:365-375
3. Clow A, Theodorou A, Jenner P, Marsden CD (1980) Cerevral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Eur J Pharmacol 63:145-157
4. Collins P, Broekkamp CLE, Jenner P, Marsden CD (1991) Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation. Psychopharmacology 103:503-512
5. Collins P, Broekkamp CLE, Jenner P, Marsden CD (1993a) Electromyographical differentiation of the components of periinput commas oral movements induced by SKF38393 and physostigmine in the rat. Psychopharmacology 112:428-436
6. Collins P, Broekkamp CLE, Jenner P, Marsden CD (1993b) Effect of chronic trifluoperazine administration and subsequent withdrawal on the production and persistence of perioral behaviours in two rat strains. Psychopharmacology 112:437-444
7. 2 receptors, inhibits rat striatal adenylate cyclase by a GTP-dependent process. Mol Pharmacol 29:113-119
8. Cote TE, Frey EA, Sekura RD (1984) Altered activity of the inhibitory guanyl nucleotide-binding component (Ni) induced by pertussis toxin. Uncoupling of Ni from receptor with continued couling of Ni to the catalytics unit. J Biol Chem 259:8693-8698
9. Crawlely JN, Hays SE, Paul SM (1981) Vagotomy abolishes the inhibitory effects of cholecystotinin on rat exploratory behaviors. Eur J Pharmacol 73:379-380
10. 3H-spiperoperidol labels dopamine receptors in pituitary and brain. Eur J Pharmacol 46:377-381
11. Creese I, Sibley DR, Hamblin MW, Left SE (1983) The classification of dopamine receptors: relationship to radiology and binding. Annu Rev Neurosci 6:43-71
12. Ellision G, See R, Levin E, Kinney J (1987) Tremorous mouth movements in rats administered chronic neuroleptics. Psychopharmacology 92:122-126
13. Emson PC, Lee CM, Rehfeld JF (1980) Cholecystokokinin octapeptide: vesicular localization and calcium dependent release from rat brain in vitro. Life Sci 26:2157-2164
14. Fuxe K, Andersson K, Locataelli V, Agnati LF, Hökfelt T, Skirboll L, Mutt V (1980) Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intrventricular injection. Eur J Pharmacol 67:329-331
15. Gerlach J, Casey DE (1988) Tardive dyskinesia (review article). Acta Psychiatr Scand 77:369-378
16. Hashimoto T, Yanagisaw N (1990) Acute reduction and long-term improvement of chorea with ceruletide (cholecystokinin analogue). J Neurol Sci 100:178-185
17. Hatta Y, Hatta S, Satio T (1993) Effect of ceruletide on the dopamine receptor-adenylate cysclasse system in streatum and frontal cortex of rats chronically treated with haloperidol. Psychopharmacology 110:383-389
18. 1 dopamine receptors in rat striatum. Eur J Pharmacol 12:31-38
19. Hökfelt T, Johannsson O, Ljungdarl, Lundberg JM, Schultzberg M (1980a) Peptidergic neurons. Nature 284:515-521
20. Hökfelt T, Skirbaoll L, Rehfeld JF, Goldstein M, Markey K, Dann O (1980b) A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence front immunohistochemistry combined with retrograde tracing. Neuroscience 5:2093-2124
21. Iversen SD, Howells RB, Huges RP (1980) Behavioral consenquences of long-term treatment with neuroleptic drugs. Adv Biochem Psychopharmacol 24:305-313
22. 2 agonist on oral movements in rats. Eur J Pharamacol 134:L83-88
23. Jurna I, Zetler G (1981) Antinociceptide effect of centrally administered caerulein and cholecystokinmin octapeptide (CCK-8). Eur J Pharamacol 73:323-331
24. Kaneda H, Shirakawa O, Dale J, Goodman L, Bachus SE, Tamminga CA (1992) Co-administration of progabide inhibits haloperidol-induced oral dysknesias. Eur J Pharmacol 212: 43-49
25. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93-96
26. Kojima T, Yamauchi T, Miyasaka M, Koshino Y, Nakane Y, Takahashi R, Shimazono Y, Yagi G (1992) Treatment of tardive dyskinesia with ceruletide:a double-blind, placebo-controlled study. Psychiatry Res 43:129-136
27. Kovac GL, Szabo G, Penke B, Telegdy G (1981) Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice. Eur J Pharmacol 69:313-319
28. Lal S, Nair NPV, Engenio H, Thavundail J, Linzondo E, Wood PL, Etienne P, Guyada H (1983) Neuroendocrine evaluation of CCK-peptides on dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatry 7:537-544
29. Lane RF, Blaha CD, Philips AG (1986) Cholecystokinin-induced inhibition of dopamiine neurotransmission: comparison with chronic haloperidol treatment. Prog Neuropsychopharmacol Biol Psychiatry 11:291-299
30. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protien measurementy with the Folin phenol reagent. J Biol Chem 193:265-275
31. Markstein R, Hökfelt T (1984) Effect of cholecystokinin-octapeptide on dopamine release from slices of cat caudate nucleus. Neuroscience 4:570-575
32. Matsubara K, Matsushita A (1985a) Possible involvement kof the central nervous system in long-term effect of caerulein on amphetamine-induced hyperactilvity in rats. Jpn J Pharmacol 39:317-321
33. Matsubara K, Matsushita A (1985b) Analysis of the long-lasting antagonistic effect of caerulein on amphetamine hyperactivity in rats. Jpn J Pharmacol 38:381-390
34. Matsumoto T, Nakahara T, Uchimura H, Hirano M, Yokoo H, Nakamura K, Oomagari K (1984) Effect of systemically administered caerulein on dopamine metavolism in rat brain. Brain Res 324:195-199
35. Moroji T, Hagino Y (1986) A behavioral pharmacological study on CCK-8 related peptides in mice. Neuropeptides 8: 273-286
36. Moroji T, Hagino Y (1987) Bilateral subdiapharagmatic vagotomy does not prevent the behavioral effects of systematically administered ceruletide in mice. Neuropeptides 9:217-224
37. Nishikawa T, Tanka M, Koga I, Uchida Y (1985) Biphasic and long-lasting effect of ceruletide on tardive dyskinesia. Psychopharmacology 86:43-44
38. Onali P, Olianas MC, Glessa GL (1984) Selective blockade of dopamine D-1 receptors by SCH23390 discloses striatal dopamine D-2 receptors mediating the inhibition of adenylate cysclase in rats. Eur J Pharmacol 99:127-128
39. Onali P, Olianas MC, Glessa GL (1985) Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum. Mol Pharmacol 28:138-145
40. 2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur J Pharmacol 186:49-59
41. 1 stimulation. Life Sci 33:2479-2482
42. Saito T, Lee JM, Tabakoff B (1985) Ethanol's effects on cortical adenylate cyclase activity. J Neurochem 44:1037-1044
43. Salomon Y, (1979) Adenylate cyclase assay. Adv Cyclic Nucleotide Res 10:35-55
44. See RE, Ellison G (1990) Intermittent and continuous haloperidol regimens produce different types of oral dyskinesia in rats. Psychopharmacology 100:404-412
45. Skirboll LR, Grace AA, Hommer DW, Rehfeld J, Goldstein M, Hökfelt T, BAunney Bs (1981) Peptide -monoamine coexistence: studies of the actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons. Neuroscience 6:2111-2124
46. 2 receptor antagonists. Psychopharmacology 98:372-379
47. Stoof JC, Kebabian JW (1981) Oppositing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294:366-368
48. Stoof JC, Kebabian JW (1984) Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci 35: 2281-2296
49. Tanaka H (1990) Absorption, distrubtion and excretion of 883-S (ceruletide diethylamine) in rats. Xenobiot Metabol Dispos 5:331-343
50. Voight MM, Wang RY (1984) In vivo release of dopamine in the nucleus accumbens of the rat: modulation by cholecystokinin. Brain Res 296:189-193
51. Waddington JL (1990) Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenominology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology 101:431-447
52. Waddinglon JL, Cross AJ, Gamble SJ, Bourne RC (1983) Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptide treatment. Science 220:530-532
53. Willner P (1984) The validity of animal models of depression. Psychopharmacology 83:1-16
54. Zetler G (1980a) Analgesia and jptosis caused by caerulein and cholecystokinin octapeptide (CCK-8). Neuropharmacology 19:415-422
55. Zetler G (1980b) Effects of cholecystoknin-like peptides on rearing activity and hexobarbital-induced sleep. Eur J Pharmacol 66:137-139
56. Zetler G (1980c) Anticonvulsant effects of caerulein and cholecystokinin octapeptide, compared with those of diazepam. Eur J Pharmacol 65:297-300
57. Zetler G (1981) Central depressant effect of caerulein and cholecystokinin octapeptide (CCK-8) differ from those of diazepam and haloperidol. Neuropharmacology 20:277-283